Announcements Trials
Browse Landscape

Phase

Phase 1 23Phase 3 19Phase 1/2 19Phase 2 15Phase 4 3Phase 2/3 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Neoplasm Metastasis 1

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × abemaciclib × Clear all
NCT04707196 2023-11-24

A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

Eli Lilly and Company

Phase 4 Completed
200 enrolled 10 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04031885 2021-08-24

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Eli Lilly and Company

Phase 4 Terminated
4 enrolled 9 charts
Breast

Breast Neoplasms

NCT03988114 2019-09-06

proMONARCH

Eli Lilly and Company

Phase 4 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡